Table 2.
Correlation between rim enhancement of CEUS and lymph node metastasis of BC
| Group | Lymph node non-metastasis group (n=208) | Lymph node metastasis group (n=540) | X2 | P |
|---|---|---|---|---|
| Peripheral halo | 311.9846 | 0.000 | ||
| Yes | 33 (15.87%) | 456 (84.44%) | ||
| No | 175 (84.13%) | 84 (15.56%) | ||
| Peripheral convergence | 7.2398 | 0.007 | ||
| Yes | 29 (13.94%) | 123 (22.78%) | ||
| No | 179 (86.06%) | 417 (77.22%) | ||
| Rim enhancement | 70.4652 | 0.000 | ||
| Radial enhancement | 162 (77.88%) | 236 (43.70%) | ||
| Non-radial enhancement | 46 (22.12%) | 304 (56.29%) | ||
| Enhancement mode | 322.2195 | 0.000 | ||
| Homogeneous | 171 (82.21%) | 69 (12.78%) | ||
| Nonhomegeneous | 37 (17.78%) | 471 (87.22%) | ||
| Enhancement amplitude | 64.5369 | 0.000 | ||
| High enhancement | 63 (30.29%) | 364 (67.41%) | ||
| Other enhancement | 135 (7.21%) | 176 (32.59%) | ||
| Enhancement sequence | 222.6093 | 0.000 | ||
| Centripetal | 42 (20.19%) | 427 (79.07%) | ||
| Non-centripetal | 166 (79.81%) | 113 (20.93%) | ||
| Enhanced boundary | 0.3981 | 0.528 | ||
| Clear | 97 (46.63%) | 238 (44.07%) | ||
| Unclear | 111 (53.37%) | 302 (55.93%) | ||
| Expanded scope after enhancement | 229.0899 | 0.000 | ||
| Yes | 38 (18.27%) | 423 (78.33%) | ||
| No | 170 (81.73%) | 117 (21.67%) |